Skip to main content
. 2021 Sep 1;9:642650. doi: 10.3389/fcell.2021.642650

FIGURE 4.

FIGURE 4

The performance of MRSB in predicting progression, survival and recurrence. (A) Progression-free survival in all patients. (B) Overall survival in the training cohort. (C) Recurrence-free survival in the training cohort. (D) Progression-free survival in the validation cohort. (E) Overall survival in the validation cohort. (F) Recurrence-free survival in the validation cohort. MRSB, methylation risk score for bladder cancer.